Related Experiment Video
Updated: Aug 19, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Predicting the risk for gastrointestinal toxicity in patients taking NSAIDs: the Gastrointestinal Toxicity Survey
Ambarish Ambegaonkar1, Kevin Livengood, Terri Craig
1Pfizer Inc., New York, NY 10017, USA.
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs in the world, but their use is often associated with adverse gastrointestinal (GI) events that may be life threatening in some patients. Development of simple questionnaires for predicting GI events in individuals taking NSAIDs may help to prevent use of these drugs in high-risk patients. The present study was undertaken to test a new questionnaire designed to identify patients at high risk for NSAID-associated GI events--the Gastrointestinal Toxicity Survey (NSAID Induced) (GITS [NI]). In this study, results for GITS (NI) were compared with those for an established questionnaire, the Stanford Calculator of Risk for Events (SCORE), in a small cohort of 400 patients. Feasible generalized least squares (FGLS) and multinomial logistic (MNL) regression were used to perform the comparison. The overall correlation between results for GITS (NI) responses and the total score for the SCORE questionnaire was 0.962 (P < .0001). The agreement between the 2 instruments with respect to their ability to predict the same risk for NSAID-induced GI events was similar for both FGLS and MNL. For 4 levels of risk, the agreement was approximately 80% between the 2 instruments. For 3 levels of risk, the agreement was approximately 90%. This study showed that results obtained with GITS (NI) are highly correlated with those from SCORE and that GITS (NI) may provide physicians with information that will help them avoid administering NSAIDs to patients who are at high risk for adverse GI reactions.
Related Concept Videos
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems related to...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...